Our @CUHematology faculty Dr. @majorajay just had a first-author publication @OncJournal defining time toxicity as a patient-reported construct in patients with lymphoma. #lymsm academic.oup.com/oncolo/arti…

The latest publication from the CUBIC Consortium in @BloodAdvances, to which our @CULymphoma faculty Drs. @majorajay & @StevenBairMD contributed. CUBIC is an ongoing multicenter study of outcomes of bispecific antibodies in broad lymphoma subtypes. #lymsm #tcellrx

Dr. @mana1981 just published a first-author review in @BloodPortfolio about next-generation therapeutics in the treatment of relapsed/refractory LBCL. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/4187…

Our @CULymphoma lead Dr. @mana1981 contributed to a multicenter study, now published @BloodCancerJnl, describing outcomes of MCL after BR and BTK inhibitors. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/4203…

What's next for lymphoma care as we enter a new immunotherapy era? In the latest Hema Now episode, host Dr Catherine Glass speaks with @mana1981, Associate Professor of Medicine and Clinical Director of the Lymphoma Program at the University of Colorado School of Medicine. From CAR-T therapies to bispecific antibodies, they discuss the breakthroughs transforming outcomes for patients with lymphoma. Together, they explore: 🔹 How CAR-T therapy has changed the treatment landscape 🔹 The growing role of bispecific antibodies 🔹 Challenges in treatment sequencing and toxicity management 🔹 Future opportunities in precision medicine and clinical trials. 🎧 Listen now: hubs.la/Q04l9zX70

New Blood Podcast episode out now! Blood editor Dr. Phillipe Armand interviews Drs. Manali Kamdar of @CUDenver and Nancy Bartlett of @WashU on their review article about relapsed/refractory large B-cell lymphoma: bloodpodcast.transistor.fm/e…

Latest from @CUHematology: our experience manufacturing our own home-grown UCD19 CAR T-cell product at the @CUAnschutz Gates Institute, now published @ASTCT_Journal. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/4224…

Historic milestone in #cancer care: HBCH&RC has achieved a landmark milestone in Pediatric Oncology by successfully treating a 15 year old #leukaemia patient with advanced CAR-T cell therapy, says (@docgulia)

Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL ashpublications.org/blood/ar…

How is CAR T driving practice forward across lymphoma subtypes? Join us at #EHA2026 for a discussion on the latest data and future directions. @Lymphoma_Doc pag.virtual-meeting.org/EHA/… @CUCancerCenter @WomenInLymphoma

Slides online from a great #ASCO2026 update on #lymphoma #CART and #bispecifics with fan-favorite @MountSinaiNYC @DrNeilLove starring Manali Kamdar @mana1981, Tycel Phillips @LymphClinician, Jason Westin @Lymphoma_Doc and Jeremy Abramson @MassGenBrigham tinyurl.com/5cf4bn8x

CONGRESS | #ASCO26 | POSTER Manali Kamdar shares results from a pooled longitudinal safety analysis of patients with LBCL who received liso-cel as 2L treatment in the TRANSFORM, PILOT, and TRANSCEND NHL 001 trials (N = 420). Incidence of Grade ≥3 neutropenia was highest from Day 0–15 (87%), consistently decreased through Month 6, then remained low (≤15%). The rate of Grade ≥3 anemia was highest from Day 0–15 (29%), declined through Month 6, then remained low (≤4%). Incidence of Grade ≥3 thrombocytopenia was highest from Day 0–Month 3 (23%–35%), declined by Month 9, then remained low (≤4%). Incidence of Grade ≥3 infections remained low in all periods (2%–6% through Month 3, then 1%–2% thereafter). Follow our live feed for more updates: bit.ly/3PJhHqD Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website. #lymphoma #lymsm #MedicalCongress @mana1981 @CUCancerCenter

Our rare disease specialist Dr. @cduarte8490 @CUHematology collaborated with @CU_pathology & @UTMDAnderson on a new publication on the diagnosis of subtypes of non-LCH. #pathtwitter cc @ZenggangPan

Biggest thanks to my mentors Dr. Alli Bock and Dr. Sairah Ahmed, my co-author Rahul Shah, and all participating CUBIC institutions. It was also very special to present on a panel led by one of my mentors at Colorado, @mana1981, and to collaborate with another CU mentor @majorajay

#ASCO26: Best part of this meeting is connecting with new people -taking a cab ride together to McCormick with @mana1981 @CUSystem @HemOncWomenDocs @SylvesterCancer

Excited to present a poster detailing my work under the guidance of @mana1981 developing a PET/CT radiomics model that may outperform standard prognostic scores in TP53-aberrant DLBCL on 6/1/26 @ASCO! asco.org/abstracts-presentat…

We are one of the first participating sites in the OncoPRO Initiative, now presented at #ASCO26. We implemented ePRO monitoring @CUCancerCenter (spearheaded by Dr. @majorajay) as part of routine cancer care to better support patients during treatment. asco.org/abstracts-presentat…

CD3xCD20 BsAb secondary CNS lymphoma (CUBIC Consortium) - 28 pts, most glofi, 64% active CNS dx, 64% prior CAR - active CNS: ORR 56% (CR 33%), CNS ORR 65% (CR 35%), 6-mo PFS 43% (CNS-PFS 53%) - no PD among pts achieving CR - responses in LM dx & post-CAR - 25% ICANS (incl G3-4) Encouraging activity as monotherapy (combo regimens no better). #lymsm nature.com/articles/s41408-0…

Congratulations to Dr. @majorajay and the L-THORs Lab on publication of one of the first studies of patient-reported time toxicity, focused on the time burden of various bispecific antibody therapies in FL and DLBCL. #lymsm cc @CUHematology @CUAnschutz @CUCancerCenter

Dr. @majorajay @CUHematology contributed to a multicenter study of nivo-AVD outcomes outside of the clinical trial setting, now published @Hemasphere_EHA. #lymsm pubmed.ncbi.nlm.nih.gov/4203…